In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Qiagen raises $627.6mm to fund DxS purchase

Executive Summary

Sample and assay developer Qiagen NV netted $627.6mm through the sale of 31.6mm common shares (including the overallotment) at $20.25 each. The offering was conducted as a public sale in the US and a sale to institutional investors outside of the US. Proceeds will be used for Qiagen's recently announced acquisition of molecular diagnostics company DxS.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register